Moreover, the EGFR inhibitor gefitinib is ineffective in treating hormone-refractory prostate cancer, a result questioning the significance of the EGFR/HER2 axis in the molecular pathogenesis of prostate cancer [11]. This evidence concerns the gene ERBB2 and Familial prostate cancer.